Case report

Simple limbal epithelial transplantation for recurrent pterygium: A case series

Zale Mednick*, Tanguy Boutin, Adi Einan-Lifshitz, Nir Sorkin, Allan Slomovic

University of Toronto, Department of Ophthalmology and Vision Sciences, Canada

ARTICLE INFO

Keywords:
- Simple limbal epithelial transplantation (SLET)
- Recurrent pterygium
- Conjunctiva
- Stem cells

ABSTRACT

Purpose: Pterygium recurrence is a common complication of pterygium removal. Multiple surgical and medical approaches have been utilized to reduce recurrence rates. The present case series proposes a novel way to treat recurrent pterygia, by using the simple limbal epithelial transplantation (SLET) technique.

Observations: The cases of four patients who presented with recurrent pterygium were reviewed. In all four of the cases reported, the SLET procedure went without complication. There were no significant recurrences at each of the patient’s most recent follow-up visits.

Conclusions and importance: This is the first report of SLET being used as a treatment modality for recurrent pterygium. Further studies are required to more reliably demonstrate the utility of the procedure in this clinical circumstance, but our results are encouraging that in select patients, this may be a viable option in treating aggressive recurrent pterygia.

1. Introduction

Pterygia are fibrovascular growths extending from the conjunctiva onto the cornea. Indications for surgical excision include extensive growth onto the cornea, induced astigmatism and ocular irritation. One of the most common complications of pterygium surgery is recurrence. Rates of recurrence vary widely in the literature. The bare sclera approach leads to recurrence in 38–88% and has largely been abandoned. Conjunctival autograft with fibrin glue has become an increasingly popular technique and has lowered recurrence rates to 5.5–11.9%. Mitomycin C (MMC) has been used as adjunct therapy to further reduce recurrences.

The current treatment paradigm for recurrent pterygia includes several options, though no option has proven impervious to failure. Techniques that employ repeat conjunctival autografting, use of amniotic membrane and application of MMC are some of the more common treatment options for recurrence and have demonstrated relatively good efficacy. Other less proven modalities include administration of subconjunctival anti-VEGF agents and injection of 5-fluorouracil (5-FU) into the pterygium.

Simple limbal epithelial transplantation (SLET) is a technique that was first described by Sangwan in 2012. It was presented in the context of treating unilateral limbal stem cell disease. The procedure involves harvesting limbal stem cells from the unaffected eye with healthy limbal stem cells. A variation of the technique has included harvesting the cells from the ipsilateral affected eye, if there is a healthy area of available limbal stem cells. The harvested stem cells are then transplanted onto the diseased area of cornea. Studies have since reported on the use of SLET for unilateral chemical burns, ocular surface squamous neoplasia and primary pterygium excision.

The following case series is the first to present SLET as a treatment option for surface reconstruction in eyes with recurrent pterygium (see Table 1).

1.1. Procedure

In the following four cases, one ophthalmologist (AS) performed the SLET procedure for cases of recurrent pterygium. While minor variations existed depending on the specific orientation of the pterygium, such as the sequence of particular steps or the site of the donor stem cells, the general steps of the procedure were essentially the same and are outlined here.

The pterygium was excised in a standard fashion with the aid of a 64-Beaver blade, Westcott scissors and forceps. Mitomycin C 0.02% was applied for two to 3 min subconjunctivally. A conjunctival peritomy was performed on the same eye to expose the limbal sclera to permit stem cell harvesting. A crescent blade was used to shave a limbal strip of approximately 4 mm × 2 mm. The limbal tissue was then cut into...
approximately ten pieces with Vannas scissors. Amniotic membrane was used to cover the cornea as well as the bare sclera deep to the excised pterygium. Fibrin glue and 8-0 vicryl sutures held the amniotic membrane in place. The harvested limbal pieces were subsequently secured with glue over the amniotic membrane along the area of limbus and cornea involved by the pterygium. A bandage contact lens (BCL) was placed over the eye at the end of the surgery.

2. Findings

2.1. Case 1

A 66-year-old male was referred for recurrent pterygium. He had undergone three pterygium excisions with conjunctival autografts (PECAs) in the left eye over the course of thirty years. Upon referral to our clinic, best-corrected visual acuity (BCVA) in the affected left eye was 20/200 + 1 pinholing to 20/80 + 1. The pterygium was nasal and measured 7.5 mm in height and extended 5 mm onto the cornea, partially covering the visual axis (Fig. 1a). Topography revealed 3.38 Diopters (D) of with-the-rule corneal astigmatism (axis 88°).

A SLET procedure was performed. At four months follow-up, the amnion was still in place with visible SLET pieces. There was some early neovascularization developing nasally and superonasally. The option of performing an avastin injection to promote regression of the neovascularization was discussed, but the patient preferred to wait and observe. At his most recent 10-month post-operative visit, vision had improved to 20/60 + 2 uncorrected and pinholed to 20/25. The amnion had still not yet fully dissolved. Corneal neovascularization was still present but appeared stable. There was an inferonasal area of symblepharon that had developed over his last few visits, but this was not felt to be a recurrence of the pterygium given its different location from the initial pathology (Fig. 1b).

Fig. 1. 1a – Large recurrent pterygium with scarring extending paracentrally, close to the visual axis. 1b–10 months following a SLET procedure, there was no evidence of recurrence, though a small area of symblepharon had formed.
18 months. Undergoing CLAG, only two of 42 eyes showed pterygium recurrence at proven. In a study of 42 eyes to simple excision with adjunctive MMC, and results demonstrated harvests. More aggressive pterygia are sometimes targeted with 5-nicotinic membrane if autologous conjunctiva is unavailable for repeat conjunctival autografting and use of amniotic membrane, becomes possible. Damage, barrier to potential conjunctivalization of the cornea, and if they are damaged, fibrovascular proliferation onto the cornea, as is seen in pterygia, becomes possible. Conventional methods of treating recurrent pterygia include adjunctive use of MMC, repeat conjunctival autografting and use of amniotic membrane if autologous conjunctiva is unavailable for repeat harvests. More aggressive pterygia are sometimes targeted with 5-FU and subconjunctival anti-VEGF, though these treatments are less proven.

Several studies have investigated the role of limbal stem cell transplantation as part of primary pterygium surgery. Conjunctival limbal autograft (CLAG) was first reported as a treatment option for aggressive and recurrent pterygia in 2000. It has since been compared to simple excision with adjunctive MMC, and results demonstrated equal or fewer recurrences in the CLAG group. In a study of 42 eyes undergoing CLAG, only two of 42 eyes showed pterygium recurrence at 18 months. While CLAG is a well-studied surgical option in limbal stem cell disease, the procedure entails dissection of a large limbal area and poses a risk of further stem cell disease at the donor site. SLET is a newer procedure which requires the harvesting of less limbal stem cell tissue and theoretically reduces the risk of iatrogenic stem cell disease; furthermore, it allows for the harvesting of limbal stem cells from the same eye. Only one other study has looked at using SLET as part of pterygium management. Ten eyes underwent SLET as part of primary pterygium excision. The results were encouraging, as there were no recurrences at eight months nor any sight-related complications.

The present case series is the first to report on the use of SLET for recurrent pterygium. The study by Bogantes et al. looked only at primary pterygium excision. The technique was also slightly different than the one used in our series, as a second layer of amniotic membrane was used on top of the stem cells, in contrast to the above cases in which a BCL was placed over the stem cells, as described by Sangwan's initial technique. Both techniques have been reported and there is no evidence to suggest superiority of one method over the other.

In terms of pterygium treatment, SLET’s utility may be greatest in cases of the recurrent ones. PECAs is a relatively less invasive and involved procedure than SLET and typically leads to fairly low pterygium recurrence rates. It is in the more aggressive and recurrent cases, however, where SLET might be considered as the more appropriate option; in such cases, removal of the pterygium may not be enough, and the limbal stem cell barrier might need to be re-populated.

While SLET was effective at preventing significant recurrence in these eyes, it is not completely surprising that corneal neovascularization did recur to a degree in two of the patients. These are aggressive pterygia that have had significant recurrence, and though the goal is to shut down any further recurrence, perhaps reducing the tempering the degree of recurrence is the best result in some of these patients.

Subconjunctival bevacizumab effectively prompted regression of these vessels in one patient, to the point that the ocular surface was sufficiently primed for a successful PKP. The use of anti-VEGF inhibitors can thus be a helpful adjunct in these cases, though observation and close monitoring is also an option.

The efficacy of anti-VEGF injections in preventing pterygium recurrence has been debated. While some studies have shown short-term regression of pterygia, both primary and recurrent, following anti-VEGF injection (Lavruc and Olup, 2012), a meta-analysis concluded that while bevacizumab is safe and well-tolerated, subconjunctival usage did not have a significant effect on reducing pterygium recurrence. More recent studies, however, have concluded that anti-VEGF injections, particularly subtenon ranibizumab, may have therapeutic utility in pterygium treatment, effectively preventing regression in up to 50% of cases.

There are several limitations of this study that should be acknowledged. While we attribute a great deal of the success of these cases to the SLET procedure, the adjunctive use of MMC makes it difficult to firmly conclude that it was the SLET and not the MMC that limited the recurrences. MMC is itself a modality used in treating recurrent pterygia. It was not felt, however, that the aggressive cases presented here would have responded sufficiently if only the MMC was used, given some of these patients had already failed MMC treatment.

The obvious limitation of this study is that it is a series of only four cases. Importantly, however, the purpose to be conveyed is that SLET is a viable surgical technique for recurrent pterygium that may help reduce further recurrences. Our results are encouraging that SLET may develop into an important part of the treatment algorithm in aggressive pterygia. Further studies are needed to more reliably assess the outcomes of this procedure in terms of long-term recurrences and complications.

4. Conclusions

SLET is a novel surgical option for the treatment of recurrent pterygia. The procedure addresses a key pathological process in pterygium development and should be considered in aggressive and recurrent cases.

Patient consent

Written consent to publish this case has not been obtained. This report does not contain any personal identifying information.

Funding

None.
Conflicts of interest

The following authors have no financial disclosures: (ZM, TB, AEL, NS, DSR).

Authorship

All authors attest that they meet the current ICMJE criteria for Authorship.

Acknowledgements

None.

References

1. Hacioglu D, Erdol H. Developments and current approaches in the treatment of pterygium. Int Ophthalmol. 2017;37:1073–1081.
2. Akinci A, Zilelioglu O. Comparison of limbal-conjunctival autograft and intraoperative 0.02% mitomycin-C for treatment of primary pterygium. Int Ophthalmol. 2007;27(5):281–285.
3. Katircoglu YA, Altiparmak U, Goktas SE, Cakir B, Singar E, Ornek F. Comparison of two techniques for the treatment of recurrent pterygium: amniotic membrane vs conjunctival autograft combined with mitomycin C. Semin Ophthalmol. 2015;30(5–6):321–327.
4. Kenyon KR, Wagener MD, Hettinger ME. Conjunctival autograft transplantation for advanced and recurrent pterygium. Ophthalmology. 1985;92:1461.
5. Hu Q, Qiao Y, Nie X, Cheng X, Ma Y. Bevacizumab in the Treatment of Pterygium: a Meta-analysis.
6. Lavric A, Olup BD. Efficiency of subconjunctival bevacizumab on pterygium. Vestnik Zdravenski. 2012(0):82.
7. Rose L, Byrd JM, Qaseem Y. Subtenon injections of ranibizumab arrest growth in early recurrent pterygium. Eye Contact Lens. 2017;43(6):399–405.
8. Said DG. Intra-lesional 5 fluouracil for the management of recurrent pterygium. Eye. 2013;27(10):1123–1129.
9. Sangwan VS, Basu S, MacNeil S, Balasubramanian D. Simple limbal epithelial transplantation (SLET): a novel surgical technique for the treatment of unilateral limbal stem cell deficiency. Br J Ophthalmol. 2012;96:931–934.
10. Mittal V, Jain R, Mittal R, Vashist U, Narang P. Successful management of severe unilateral chemical burns in children using simple limbal epithelial transplantation (SLET). BJO (Br J Ophthalmol). 2016;100(8).
11. Mittal V, Narang P, Menon V, Mittal R, Honavar S. Primary simple limbal epithelial transplantation along with excisional biopsy in the management of extensive ocular surface squamous neoplasia. Cornea. 2016;35(12):1651–1652.
12. Hernandez-Bogantes E, Amescua G, Navas A, et al. Minor ipsilateral simple limbal epithelial transplantation (mini-SLET) for pterygium treatment. Br J Ophthalmol. 2015;99(12):1599–1609.
13. Kwok LS, Corneoreo MT. A model for pterygium formation. Cornea. 1996;15(3):219–224.
14. Corneoreo MT, Di Girolamo N, Wakefield D. The pathogenesis of pterygia. Curr Opin Ophthalmol. 199;10(4):282–288.
15. Chu D, Reed M. Pterygium excision with mini-conjunctival graft: a new surgical approach. Invest Ophthalmol Vis Sci. 2003;44 E Abstract 1330.
16. Gris O, Gued J, del Campo Z. Limbal-conjunctival autograft transplantation for the treatment of recurrent pterygium. Ophthalmology. 2000;107(2):276–273.
17. Akinci A, Zilelioglu O. Comparison of limbal-conjunctival autograft and intraoperative 0.02% mitomycin-C for treatment of primary pterygium. Int Ophthalmol. 2007;27(5):281–285.
18. Melek I, Zghal I, Chebbi A, et al. Conjunctival limbal autograft versus simple excision with intraoperative mitomycin C in pterygium surgery: a comparative study. J Fr Ophthalmol. 2013;36(3):230–235.
19. Mahdy S, Bhatia J. Treatment of primary pterygium: role of limbal stem cells and conjunctival autograft transplantation. Eur J Ophthalmol. 2009;19(5):729–732.